Article
Routine Tumor Testing for Homologous Recombination Deficiency in Patients With High Grade Epithelial Ovarian Cancer at a Statewide Gynecological Cancer Service in Western Australia: An Observational Study.
Cancer reports (Hoboken, N.J.) - 1 Sept 2025
Planisamy Kaamini, Ctori Elena, Amanuel Benhur, Allanson Emma R, Ayres Chloe, Buck Martin, Howard Giselle, Leung Yee, Meniawy Tarek, Mohan G Raj K A, Nichols Cassandra B, Pallayoor Navin David, Cohen Paul A
Abstract excerpt
BACKGROUND: Poly-ADP ribose polymerase inhibitors have been shown to improve progression-free survival in patients with advanced high-grade epithelial non-mucinous ovarian cancers characterized by a deficiency in homologous recombination (HRD). Guidelines recommend all patients with advanced high-grade epithelial ovarian cancer undergo genomic tumor testing for HRD. Our aim was to evaluate the first year of HRD...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.